(2,3-Diphenyloxiran-2-yl)-phenylmethanone | 6975-08-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (2,3-Diphenyloxiran-2-yl)-phenylmethanone
• CAS: 6975-08-2
• 化学式: C₂₁H₁₆O₂
• 分子量: 300.3
• InChiKey: WLBCXDDYEIKDGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  29.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] METHOD OF TREATING IMMUNOLOGICAL DISORDERS MEDIATED BY T-LYMPHOCYTES<br/>[FR] PROCEDE DE TRAITEMENT DES TROUBLES IMMUNOLOGIQUES INDUITS PAR LES LYMPHOCYTES T
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2000023060A2

  公开（公告）日：2000-04-27

  The use of soluble epoxide hydrolase inhibitors in the treatment of T-lymphocyte mediated immunological disorders is described either as monotherapies or as part of combination therapies for such disorers.
• [EN] NOVEL METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY<br/>[FR] NOUVEAUX PROCÉDÉS DE TRAITEMENT D'UN OS PAR MODULATION D'UNE VOIE MÉTABOLIQUE OU PAR SIGNALISATION DE L'ACIDE ARACHIDONIQUE
  申请人：ACCELALOX INC

  公开号：WO2009105723A2

  公开（公告）日：2009-08-27

  Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods rely on in vivo or ex vivo modulation of an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors, leukotriene A4 hydrolase inhibitors, and/or leukotriene B4 receptor antagonists. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.
• [EN] METHODS OF TREATING MENTAL DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES MENTAUX
  申请人：UNIV CALIFORNIA

  公开号：WO2017120012A1

  公开（公告）日：2017-07-13

  This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.
• [EN] METHODS OF IMPROVING CANCER CHEMOTHERAPY<br/>[FR] PROCÉDÉS D'AMÉLIORATION D'UNE CHIMIOTHÉRAPIE ANTICANCÉREUSE
  申请人：UNIV CALIFORNIA

  公开号：WO2019040319A1

  公开（公告）日：2019-02-28

  Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase ("COX") -1, COX-2, and 5-lipoxygenase ("5-LOX"). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.